NCT07118319RECRUITINGanonymous

A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis

Sponsor

Source record

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) targeting motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS).

Indication / condition

AI-normalized

Amyotrophic Lateral Sclerosis (ALS)

Intervention

Source record

Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN), Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)

Related intelligence directories

Indication directory: Amyotrophic Lateral Sclerosis (ALS)Modality directory: small molecule Target directory: Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) targeting motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS).

Source & freshness

Source record

NCT ID

NCT07118319

Original source

ClinicalTrials.gov

Source last updated

Detailed source ingestion pending.

Ingested at

Jul 10, 2026

Internal sync

Jul 10, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT07118319

Title

A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis

Sponsor

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

Status

RECRUITING

Phase

Phase 1

Condition raw

Amyotrophic Lateral Sclerosis (ALS)

Condition normalized

Amyotrophic Lateral Sclerosis (ALS)

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) targeting motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS).

Target normalized

Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) targeting motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS).

Interventions

Public preview

Source record

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. is advancing a Phase I clinical trial for XS228CN, a novel therapy utilizing iPSC-derived motor neuron progenitor cells aimed at treating ALS. The ALS market is characterized by a high unmet need, with limited effective therapies currently available. The successful demonstration of safety and preliminary efficacy could position XS228CN as a significant player in the ALS treatment landscape, potentially attracting partnerships or acquisition interest from larger biopharmaceutical companies. Given the trial's focus on a debilitating and progressive disease, positive outcomes could enhance the company's valuation and market presence.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jul 28, 2026

Report code

NCT07118319-Jul 28, 2026

NCT ID

NCT07118319

Status

RECRUITING

Phase

Phase 1

Sponsor

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedDetailed source ingestion pending.

Internal syncJul 10, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07118319

Indication

Amyotrophic Lateral Sclerosis (ALS)

Modality

small molecule

Target

Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) targeting motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS).

Intervention

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.